alexa Medical Oncology And Ovarian Cancers: Overview And Recent Advances
ISSN: 2161-0932

Gynecology & Obstetrics
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

2nd International Conference on Pediatrics & Gynecology-2012

P. S. Dattatreya
Track 5, 7, 8, 10 & 11: J Pediatr Therapeut
DOI: 10.4172/2161-0665-S1.011
Abstract
The WHO classification of ovarian tumors has four broad sub groups: Epithelial tumors, Sex cord-stromal tumors, Germ cell tumors, and Gonadoblastoma. The surgical management for dyspgerminomas and non?dysgerminomas is fertility sparing surgery (FPS). Chemotherapy with protocols like PEB is advocated for germ cell tumors > stage IA. With the PEB protocol for 3 ? 4 cycles, 80% regain normal menstrual function with several documented pregnancies. Various phase 3 trials in advanced EOCs (Epithelial Ovarian Cancers) have established Paclitaxel + Carboplatin every 3 weeks for 6 cycles as the standard of care (2004 GCIG recommnended standard) with a median PFS of 15.4 ? 16.4 months and 30?35% 5 year overal survival (OS). Substitution of Paclitaxel (with Docetaxel or PLD), maintenace Paclitaxel for 1 year, Consolidation chemotherapy with Topotecan, adding a 3rd drug to Paclitaxel and Carboplatin have all shown no advantage. Intraperitoneal chemotherapy and dose?dense chemotheray have shown an OS benefit at the expense of higher grade 3 and grade 4 side effects. The GOG 218 trial incorporating Avastin for 15 months and the ICON7 trial incorporating Avastin for 12 months showed a statically significant improvement in the PFS when compared to Paclitaxel + Carboplatin. In Platinum sensitive recurrent EOC, adding Avastin to Gemcitabine + Carboplatin (as in the OCEANS trial) showed a significant PFS benefit. In platinum resistant recurrent EOC, adding Avastin to various chemotherapy options (Investigator?s choice) showed a significant PFS benefit. Avastin, therefore, seems to be the ideal partner of choice with chemotherapy in advanced EOC as first-line and in platinum-sensitive and platinum-resistant recurrent ovarian cancer.
Biography
P. Satya Dattatreya obtained his DM training in medical oncology from the Gujarat Cancer and Research Institute, Ahmedabad and his DNB in medical oncology from the NBE, New Delhi. He is presently working as a senior consultant in medical oncology at the Omega hospitals, Banjara hills, Hyderabad.
image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords